. Percentage of patients* by calendar period and type of initial treatment for first primary malignancy in adulthood, 9 SEER registries, Abbreviation: Surveillance, Epidemiology and End Results (SEER). * The study population was restricted to patients who were diagnosed with a first primary malignancy between ages 20-84 years during and who survived at least one year following diagnosis. The reported percentages are minimum estimates of the total number of patients who received chemotherapy because of under-ascertainment of initial chemotherapy treatment by the SEER cancer registries and because some patients may receive subsequent chemotherapy. Although initial chemotherapy, particularly treatments received in the outpatient setting, is known to be underascertained and the degree of under-ascertainment may vary by calendar period and first primary malignancy, observed trends in chemotherapy use generally are consistent with more detailed patterns of care studies based on medical record re-abstraction and physician verification of treatment.
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Figure S1 references: P trend =0.181 Abbreviations: confidence interval (CI); therapy-related acute myeloid leukemia (tAML); standardized incidence ratio (SIR); Surveillance, Epidemiology and End Results (SEER). Exact cell counts with <3 patients are suppressed to protect patient confidentiality. # indicates P<0.05. * Includes first primary malignancies after which at least 50 tAMLs were reported. ** SIRs are unadjusted. † Derived from Poisson regression models adjusted for age at first primary malignancy diagnosis, receipt of initial radiotherapy, sex (for lung and bronchus, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma), stage (for lung and bronchus, female breast, ovary), and latency (overall: 1.0-4.9, 5.0-9.9, 10+ years, except for lung and bronchus: 1-4.9, 5+ years; <5 years: 1.0-2.9, 3.0-4.9 years). P trend =0.177 Abbreviations: confidence interval (CI); excess absolute risk (EAR); therapy-related acute myeloid leukemia (tAML); standardized incidence ratio (SIR); Surveillance, Epidemiology and End Results (SEER). # indicates P<0.05. * Includes first primary malignancies after which at least 50 tAMLs were reported. ** SIRs and EARs are unadjusted. † Derived from Poisson regression models adjusted for year of first primary malignancy diagnosis, receipt of initial radiotherapy, sex (for lung and bronchus, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma), stage (for lung and bronchus, female breast, ovary), and latency (overall: 1.0-4.9, 5.0-9.9, 10+ years, except for lung and bronchus 1-4.9, 5+ years).
